Evaluation of 0.18% HA emulsion eyedrop for moderate to severe dry eye
| ISRCTN | ISRCTN17861788 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN17861788 |
| IRAS number | 272716 |
| Secondary identifying numbers | ID19-42/ HPCLIDM052019003, IRAS 272716 |
- Submission date
- 02/12/2019
- Registration date
- 30/12/2019
- Last edited
- 18/03/2025
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Eye Diseases
Plain English summary of protocol
Background and study aims
Dry eye or meibomian gland dysfunction (MGD) is a complex condition for which numerous management products have been developed to deal with the many causes of the condition. Dry eye has significant impact on quality of life and is a burden. 0.18% emulsion CE-marked eyedrop manufactured by Horus Pharma has the potential to provide dry eye relief for moderate to severe dry eye based on the composition of the eyedrop.
The purpose of this study is to evaluate eyedrop performance and its beneficial effect in people with moderate to severe dry eye problems after one month of daily use. There are two phases of the study. The first phase is to determine the effect of a single instillation of the eyedrop over a two-hour period. The second phase is to determine the eyedrop effect after repeated daily use over a one-month duration.
Who can participate?
Adults who are between 18 to 75 years old, healthy, currently not wearing contact lenses or using the study eyedrop and have moderate to severe dry eye signs and symptoms.
What does the study involve?
Participants will be given eye drops to use instead of their usual eye drops for one month.
What are the possible benefits and risks of participating?
Participants may not directly benefit from taking part in this study but will have the opportunity to try a different eyedrop to manage their dry eye condition and will also receive a free examination of the front part of their eyes and free supply of the study product during their participation in the study. Due to the nature and short duration of the study, the risks of participating are considered minimal.
Where is the study run from?
Ocular Technology Group - International (UK)
When is the study starting and how long is it expected to run for?
November 2019 to June 2020
Who is funding the study?
Laboratoires Horus Pharma, France
Who is the main contact?
Kishan Patel
kpatel@otg.co.uk
Contact information
Public
Ocular Technology Group - International
66 Buckingham Gate
London
SW1E 6AU
United Kingdom
| Phone | +44 (0)20 7222 4224 |
|---|---|
| kpatel@otg.co.uk |
Study information
| Study design | Interventional non-randomised single centre study |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Non randomised study |
| Study setting(s) | Other |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details to request a participant information sheet |
| Scientific title | 0.18% HA emulsion Characterisation of Clinical Performance and Acceptance |
| Study objectives | Phase 1 of this study is an exploratory study hence no hypothesis will be tested Phase 2: After one-month use of eyedrop the overall subjective ocular comfort visual analog scale (VAS) score rating and ocular surface status will improve for the overall study population, irrespective of the dry eye etiology |
| Ethics approval(s) | Approved 11/11/2019, East of England - Cambridge Central Ethics Committee (The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS, UK; +44 (0)207 104 8234; NRESCommittee.EastofEngland-CambridgeCentral@nhs.net), ref 19/EE/0315 |
| Health condition(s) or problem(s) studied | Dry eye/Meibomian Glands Dysfunction (MGD) |
| Intervention | Emulsion eyedrop containing 0.18% sodium hyaluronate, phospholipids, triglycerides and alpha lipoic targets all three layers of the tear film, as well as being hypoosmolar hence addressing the inflammatory component of dry eye. This study will characterise the short and long-term clinical performance and acceptance of the emulsion eyedrop. For the short term (Phase 1), the effect of a single instillation of the eyedrop before and over a two-hour period post instillation will be quantified for tear film characteristics and subjective acceptance (comfort and vision). For the long-term (Phase 2) the effect of the repeated use of the eyedrop over a one month use period on overall subjective comfort improvement before and after use will be measured. Forty symptomatic dry eye participants will be enrolled. There will be three study visits (for phase 1 and 2) and two study visits (for phase 2 only) over a 45-day period. Participants will need to stop using habitual eyedrops two days prior to the first study visit and during the study period. The potential participants will attend the clinic for Visit 1 to obtain informed consent and evaluate suitability to take part in the investigation. The participants will be asked to complete a series of questionnaires to capture demographics, medical & ocular history, medications, ocular symptomatology (Ocular Surface Dryness Index - OSDI and Visual Analog Scale -VAS for eye comfort, vision and eye sensations experienced), vision measurement with spectacle correction, eye examination using a microscope and a beam of light (slit lamp). If meeting the investigation’s inclusion and exclusion criteria, participants will be enrolled, baseline measurements will be performed: visual acuity, non-invasive tear film digital videos recording, tear film collection, measurement of tear film evaporation, digital eye photos and conjunctival impression. For those in both Phase 1 and 2, the study visits are described below. At the end of the first study visit, the next visit will be scheduled 2-5 days later. At Visit 2 (Phase 1 test/Phase 2 dispensing visit), the study staff will place one drop of the study eyedrop into each eye. Evaluations will be performed prior to the eyedrop instillation (pre), post eyedrop instillation at multiple time points over 2-hour period. The study eyedrop will be dispensed for the participants to take home and the eyedrop will be used every day. A short secure remote electronic survey will be completed every 4 days, like the questionnaires at the clinic. At Visit 3 (35 ±5 Days after Visit 2), the study visit will follow the same routine as Visit 1. At the end of the visit, participants will be discharged from the study. If in Phase 2 only, the study visits are described below. At the end of the first study visit, the study eyedrop will be dispensed to take home and the participants will need to use the study eyedrop every day. Participants will then be scheduled to return for Visit 2 about a month later (35 ±5 Days after Visit 2). A short secure remote electronic survey will be completed every 4 days, like the questionnaires at the clinic. At Visit 2, the study visit will follow the same routine as Visit 1, involving completion of a series of questionnaires, examination of ther eyes using a microscope and a beam of light (slit lamp), and vision measurements. The same specialized measurements will be repeated and at the end of the visit, participants will be discharged from the study. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Neovis® Total Multi eyedrop |
| Primary outcome measure | 1. Tear film characteristics using non-invasive digital recording of the tear film using the Tearscope lighting and the slit-lamp at all visits 2. Subjective comfort ratings using visual analog scale (VAS) 0-100 at all visits |
| Secondary outcome measures | None |
| Overall study start date | 13/09/2019 |
| Completion date | 01/06/2020 |
Eligibility
| Participant type(s) | Healthy volunteer |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | Up to 60 symptomatic dry eye participants to be screened with a view to enroll 40 participants into the study. |
| Total final enrolment | 40 |
| Key inclusion criteria | 1. Age 18 to 75 years 2. Moderate to severe dry eye sufferers defined by an OSDI score > 23 3. Be willing to stop using habitual eyedrops two days prior to the first study visit 4. Best corrected visual acuity of at least 20/30 in each eye 5. Have read and understood the Participant Information Sheet and Informed Consent in English 6. Be willing and able to adhere to the instructions set in the clinical protocol and maintain the appointment schedule |
| Key exclusion criteria | 1. Contact lens wearers 2. Severe ocular dryness with one of the conditions; eyelid or blinking malfunction, corneal disorders not related to dry eye syndrome, ocular metaplasia, filamentous keratitis, corneal neovascularization 3. Current user of the study products 4. Ocular anterior segment infection, inflammation, abnormality, or active disease within the last 12 months not related to dry eye that would contraindicate study participation 5. Use of systemic or ocular medications (such as isotretinoïd, cyclosporine, tacrolimus, sirolimus, pimecrolimus, punctal plugs) or dry eye therapy (intense pulse light, stem cells) that could be contraindicated as determined by the investigator 6. Monocular participants (only one eye with functional vision) 7. Any moderate or severe ocular condition observed during the slit-lamp examination at the enrolment visit 8. History of herpetic keratitis, ocular surgery or irregular cornea 9. Known pregnancy or lactation during the study period 10. Enrolment of the investigator or his/her staff, family members of the investigator, family members of the investigator’s staff, or individuals living in the households of these individuals 11. Participation in any clinical trial within 30 days of the enrollment visit |
| Date of first enrolment | 12/11/2019 |
| Date of final enrolment | 01/05/2020 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
London
SW1E 6AU
United Kingdom
Sponsor information
Industry
148 Avenue Georges Guynemer
Cap Var Saint-Laurent du Var
06700
France
| Phone | +33 (0)4 83 32 32 91 |
|---|---|
| Camille.Guerin@horus-pharma.fr | |
| Website | http://www.horus-pharma.com/en/ |
Funders
Funder type
Industry
No information available
Results and Publications
| Intention to publish date | 01/02/2021 |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Data sharing statement to be made available at a later date |
| Publication and dissemination plan | Conference presentation, journal publication. |
| IPD sharing plan | The current data sharing plans for this study are unknown and will be available at a later date |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Basic results | version V0.1 | 28/10/2020 | 19/11/2020 | No | No |
| HRA research summary | 28/06/2023 | No | No | ||
| Results article | 13/03/2025 | 18/03/2025 | Yes | No |
Additional files
- ISRCTN17861788_BasicResults_V0.1_28Oct2020.docx
- uploaded 19/11/2020
Editorial Notes
18/03/2025: Publication reference added.
19/11/2020: The basic results of this trial have been uploaded as an additional file.
10/12/2019: Trial’s existence confirmed by East of England - Cambridge Central Ethics Committee
